AMRX icon

Amneal Pharmaceuticals

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 36.8%
Negative

Positive
Zacks Investment Research
5 days ago
Is it a Good Idea to Invest in Amneal Pharmaceuticals Stock Now?
AMRX is building momentum with growth across specialty drugs and biosimilars, supported by new launches and a diversified portfolio.
Is it a Good Idea to Invest in Amneal Pharmaceuticals Stock Now?
Positive
Zacks Investment Research
13 days ago
Why Amneal Pharmaceuticals (AMRX) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Amneal Pharmaceuticals (AMRX) is a Top Growth Stock for the Long-Term
Positive
Zacks Investment Research
16 days ago
3 Reasons Why Growth Investors Shouldn't Overlook Amneal (AMRX)
Amneal (AMRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
3 Reasons Why Growth Investors Shouldn't Overlook Amneal (AMRX)
Positive
Zacks Investment Research
16 days ago
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?
Positive
Zacks Investment Research
23 days ago
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)
Neutral
GlobeNewsWire
24 days ago
Amneal Reports First Quarter 2026 Financial Results
‒  Q1 2026 Net Revenue of $723 million ; GAAP Net Income of $62 million ; Diluted Income per Share of $0.19 ‒ ‒ Adjusted EBITDA of $202 million ; Adjusted Diluted EPS of $0.27 ‒ ‒ No Change from Preliminary Results Previously Announced on April 22, 2026 ‒ ‒ Affirms Previously Announced Increase in 2026 Full Year Guidance ‒
Amneal Reports First Quarter 2026 Financial Results
Positive
Zacks Investment Research
1 month ago
Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Amneal (AMRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts See a 34.77% Upside in Amneal (AMRX): Can the Stock Really Move This High?
The consensus price target hints at a 34.8% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 34.77% Upside in Amneal (AMRX): Can the Stock Really Move This High?
Positive
Zacks Investment Research
1 month ago
Amneal Pharmaceuticals (AMRX) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Amneal Pharmaceuticals (AMRX) is a Top-Ranked Momentum Stock: Should You Buy?
Positive
Zacks Investment Research
1 month ago
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?